Fucikova Jitka, Rakova Jana, Hensler Michal, Kasikova Lenka, Belicova Lucie, Hladikova Kamila, Truxova Iva, Skapa Petr, Laco Jan, Pecen Ladislav, Praznovec Ivan, Halaska Michael J, Brtnicky Tomas, Kodet Roman, Fialova Anna, Pineau Josephine, Gey Alain, Tartour Eric, Ryska Ales, Galluzzi Lorenzo, Spisek Radek
Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Sotio, Prague, Czech Republic.
Clin Cancer Res. 2019 Aug 1;25(15):4820-4831. doi: 10.1158/1078-0432.CCR-18-4175. Epub 2019 May 10.
In multiple oncological settings, expression of the coinhibitory ligand PD-L1 by malignant cells and tumor infiltration by immune cells expressing coinhibitory receptors such as PD-1, CTLA4, LAG-3, or TIM-3 conveys prognostic or predictive information. Conversely, the impact of these features of the tumor microenvironment on disease outcome among high-grade serous carcinoma (HGSC) patients remains controversial.
We harnessed a retrospective cohort of 80 chemotherapy-naïve HGSC patients to investigate PD-L1 expression and tumor infiltration by CD8 T cells, CD20 B cells, DC-LAMP dendritic cells as well as by PD-1, CTLA4, LAG-3, and TIM-3 cells in relation with prognosis and function orientation of the tumor microenvironment. IHC data were complemented with transcriptomic and functional studies on a second prospective cohort of freshly resected HGSC samples. analysis of publicly available RNA expression data from 308 HGSC samples was used as a confirmatory approach.
High levels of PD-L1 and high densities of PD-1 cells in the microenvironment of HGSCs were strongly associated with an immune contexture characterized by a robust T1 polarization and cytotoxic orientation that enabled superior clinical benefits. Moreover, PD-1TIM-3CD8 T cells presented all features of functional exhaustion and correlated with poor disease outcome. However, although PD-L1 levels and tumor infiltration by TIM-3 cells improved patient stratification based on the intratumoral abundance of CD8 T cells, the amount of PD-1 cells failed to do so.
Our data indicate that PD-L1 and TIM-3 constitute prognostically relevant biomarkers of active and suppressed immune responses against HGSC, respectively.
在多种肿瘤学背景下,恶性细胞表达共抑制配体PD-L1以及表达共抑制受体(如PD-1、CTLA4、LAG-3或TIM-3)的免疫细胞浸润肿瘤可传达预后或预测信息。相反,肿瘤微环境的这些特征对高级别浆液性癌(HGSC)患者疾病结局的影响仍存在争议。
我们利用一个包含80例未接受过化疗的HGSC患者的回顾性队列,研究PD-L1表达以及CD8 T细胞、CD20 B细胞、DC-LAMP树突状细胞以及PD-1、CTLA4、LAG-3和TIM-3细胞的肿瘤浸润情况,以及它们与肿瘤微环境的预后和功能方向的关系。免疫组化数据通过对另一组新鲜切除的HGSC样本的前瞻性队列进行转录组学和功能研究得到补充。对来自308个HGSC样本的公开可用RNA表达数据的分析用作验证方法。
HGSCs微环境中高水平的PD-L1和高密度的PD-1细胞与以强大的T1极化和细胞毒性方向为特征的免疫背景密切相关,这能带来更好的临床益处。此外,PD-1 TIM-3 CD8 T细胞呈现出功能耗竭的所有特征,并与不良疾病结局相关。然而,尽管基于肿瘤内CD8 T细胞的丰度,PD-L1水平和TIM-3细胞的肿瘤浸润改善了患者分层,但PD-1细胞的数量却未能如此。
我们的数据表明,PD-L1和TIM-3分别构成针对HGSC的活跃和抑制免疫反应的预后相关生物标志物。